2 recruiting, 1 active not recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Allogeneic HSCT: new trials by email Literature Review of Allogeneic HSCT trials Research Report on Allogeneic HSCT
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation Melphalan, Sirolimus, Total Body Irradiation (TBI) - Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 260 | 2022-11-18 | 2026-10-16 |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine - Hematologic Neoplasms | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 320 | 2021-09-23 | 2026-10-16 |
| Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL CD19/CD22 CAR-T - B-ALL | Phase 1 / Phase 2 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 50 | 2020-07-27 | 2023-02-22 |
Hematologic Neoplasms (2) · Bronchiolitis Obliterans Syndrome (1) · Leukemia, Myeloid, Acute (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
National Cancer Institute (NCI) (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1)
United States (2) · Russia (1)
Christopher G Kanakry, M.D. (2) · Michael Maschan (1)